MLYS

Mineralys

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 0

consensus rating "Strong Buy"

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About MLYS

Mineralys Therapeutics, Inc.

A biopharmaceutical company focused on developing innovative treatments for hypertension and cardiovascular disease

Industry

Pharmaceutical

Established Date

05/31/2019

Listing Date

02/10/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.mineralystx.com

Security Type

Common stock

Office address

150 N. Radnor Chester Road, Suite F200, Radnor, PA 19087

Business

Introduction

Mineralys Therapeutics, Inc., originally formed on May 31, 2019, is a Delaware corporation. The company is a clinical-stage biopharmaceutical company focused on developing drugs to treat diseases caused by abnormally elevated aldosterone. The Company's product candidate, chloroprost, is a proprietary oral highly selective aldosterone synthase inhibitor (ASI) originally developed by the Company for the treatment of patients with uncontrolled hypertension (uHTN), defined as individuals whose blood pressure cannot reach 130/80mmHg or less despite taking two or more antihypertensive drugs or resistant hypertension (rHTN). In the United States, there are more than 115 million patients with persistent hypertension (BP) or hypertension, and more than half of the patients fail to achieve the blood pressure target, which is 130/80 mmHg with currently available drugs. More than 30 million treated patients did not meet blood pressure targets, and about 20 million of them had systolic blood pressure levels exceeding 140 mmHg. High blood pressure persisted despite taking two or more drugs, and the risk of mortality from cardiovascular disease or stroke was 1.8 times and 2.5 times, respectively. In a Phase 2 clinical trial evaluating 200 uHTN and rHTN (target HTN) subjects, lolonprost showed a clinically and statistically significant drop in blood pressure with once-daily dosing and was well tolerated. In addition to high blood pressure, the company also intends to develop chloroprost for the treatment of chronic kidney disease (CKD).

Company Financials

EPS

MLYS has released its 2024 Q4 earnings. EPS was reported at -0.98, versus the expected -1.08, beating expectations. The chart below visualizes how MLYS has performed over recent quarters, highlighting trends in earnings surprises.